Methods of treating colorectal cancer using an Anti-CTLA4 antibody

Administering a CTLA-4 binding antibody with specific CDR sequences addresses the limitations of current treatments by effectively reducing tumor burden and enhancing T-cell activation in metastatic colorectal cancer, particularly in non-liver metastases, offering a novel therapeutic approach for non-MSI-H/dMMR patients.

WO2025245317A1PCT designated stage Publication Date: 2025-11-27AGENUS INC
View PDF 2 Cites 0 Cited by

Patent Information

Application Number
PCT/US2025/030515
Authority / Receiving Office
WO · WO
Patent Type
Applications
Current Assignee / Owner
Priority Date
2024-05-23
Filing Date
2025-05-22
Publication Date
2025-11-27

AI Technical Summary

Technical Problem

Current treatments for metastatic colorectal cancer, particularly in non-microsatellite instability-high/mismatch repair deficient (non-MSI-H/dMMR) patients, are modestly effective and limited to treating liver metastases, leaving a significant unmet medical need for effective therapies that can target metastases in other locations.

Method used

Administration of an antibody that specifically binds to human Cytotoxic T-Lymphocyte Antigen 4 (CTLA-4), with specific CDR sequences, to reduce tumor burden and enhance T-cell activation in subjects with metastatic colorectal cancer, including non-liver metastases such as adrenal gland, bone, brain, kidney, lung, lymphatic system, lymph nodes, peritoneum, pleura, retroperitoneum, soft tissue, and spleen.

Benefits of technology

The antibody effectively reduces tumor burden and enhances T-cell activation, providing therapeutic benefits for metastatic colorectal cancer, including unresectable and non-MSI-H/dMMR cases, with potential for administration before surgery and in combination with other antibodies like PD-1.

✦ Generated by Eureka AI based on patent content.

Smart Images

  • Figure US2025030515_27112025_PF_FP_ABST
    Figure US2025030515_27112025_PF_FP_ABST
Patent Text Reader

Abstract

Provided are methods for treating metastatic colorectal cancer with an antibody that specifically binds to human Cytotoxic T-Lymphocyte Antigen 4 (CTLA-4). Also provided herein are methods for administering an antibody that specifically binds to human CTLA-4 that results in a reduction of tumor burden in a subject. The methods may comprise a therapeutically effective amount that safely and effectively treats metastatic colorectal cancer. The methods may further comprises a therapeutically effective amount that safely and effectively reduces the tumor burden in a subject that has metastatic colorectal adenocarcinoma.
Need to check novelty before this filing date? Find Prior Art

Citation Information

Patent Citations

  • Anti-CTLA-4 antibodies and methods of use thereof

    US20180185481A1

  • Methods of treating colorectal cancer using an Anti-CTLA4 antibody

    WO2024097200A1